Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2003

View Archived Issues

OBI-1 undergoes testing in hemophilia A patients

Phase II trial of repifermin for chronic venous ulcers does not meet primary endpoint

Safety and efficacy of LymphoStat-B for SLE evaluated in phase II clinical trial

FDA advisory committee recommends expanded label for Provigil

Clinical evaluation of dopamine D3 receptor as a target

Mood-stabilizing properties described for anticonvulsants

Antagonists of VR1, mGluR1 and/or mGluR5 receptors claimed by Euroceltique

Novel muscarinc M2 agonists with potential utility in cardiovascular disorders

Boehringer Ingelheim presents new HCV NS3 inhibitors

New alphavbeta6 integrin inhibitors and their use described by Merck KGaA

Guanidine-based melanocortin MC4 agonists covered by Chiron patent

French team prepares and tests new insulin mimetics

Preliminary phase III results for modified-release indiplon

Milestone achievement in Affinium/Pfizer alliance

Five-year CHAMPIONS data support early initiation of Avonex for MS

Thyrogen indication extended in Europe

Amendment to Epimmune contract to include smallpox as target

Merck exercises option in Celltech PDE4 collaboration

Integrin antagonists useful for angiogenesis-related ocular diseases

Additional funding for development of MVA-BN as smallpox vaccine

Second-generation peptide deformylase inhibitors for RTIs presented at ICAAC meeting

Characterization of new 5-HT1B antagonist reveals anxiolytic/antidepressant properties

Successful interim analysis of phase II alfimeprase study

Major study to directly compare PEG-Intron and Pegasys for HCV

Semisynthetic ketolide antibacterial agents designed at J&J and Kosan

HuMax-EGFr tested in a new phase I/II trial in head and neck cancer

New inhibitors of dipeptidyl-peptidase IV with blood glucose-lowering activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...